NCT07845513Not yet recruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity
A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-08653944 FOLLOWING SINGLE DOSE SUBCUTANEOUS ADMINISTRATION IN OTHERWISE HEALTHY CHINESE ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to learn about: * How PF-08653944 is changed and removed from the body after taken * Safety of PF-08653944 * The extent to which side effects can be tolerated after taking PF- 08653944 for the possible treatment of heart failure This study is seeking participants who: * Are healthy Chinese adults who are aged 18 years and older * Have body mass index of 24 - 45 kilograms/meter2 * Have a total body weight of equal to or more than 50 kilograms (110 pounds) * Do not have prior significant medical conditions, history of drug or alcohol abuse All participants in this study will receive a single dose of PF-08653944 at the study clinic. The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe. Participants will take part in this study for around 16 weeks. During this time, they will have 6 study visits at the study clinic.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 21 Feb 2027
- Lead sponsor
- Pfizer
- Diseases
- Obesity
- NCT number
- NCT07845513
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 16
- From 1 Nov 2026 to the primary completion date, 21 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Clinically significant gastric emptying abnormality or chronically taking drugs that directly affect GI motility.
- Prior participation in any study involving PF-08653944 with at least one dose received.
Other illness
- Clinically significant medical conditions including hematologic, renal, endocrine, pulmonary, gastrointestinal (including pancreatitis, gallbladder disease, clinically relevant gastric emptying disorders), cardiovascular, hepatic, psychiatric, neurologic, or severe allergic diseases.
- Personal or first-degree family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), or suspected MTC.
- Active or recent suicidal ideation in the past year, suicidal behavior within the past 5 years, or any psychiatric condition that increases risk in the investigator's judgment.
- Known hypersensitivity to PF-08653944, GLP-1 receptor agonists, or any excipients.
Other
- Pregnant or breastfeeding women, or those planning pregnancy during the study.
- Acute gastrointestinal symptoms at screening or Day -1.
Who the study is looking for
- Participants 18 years of age or older at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
- BMI of 24-45 kg/m2; and a total body weight \>50 kg (110 lb).
- Chinese participants are defined as individuals currently residing in mainland China who were born in China and have both parents of Chinese descent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Friendship Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.